Last updated on November 2018

A Study of Crisaborole Ointment 2%; Crisaborole Vehicle; TCS and TCI in Subjects Aged 2 Years With Mild-moderate AD


Brief description of study

This 4-week study will evaluate the safety and efficacy of crisaborole ointment 2%; crisaborole vehicle; topical corticosteroid and topical calcineurin inhibitor, applied twice daily (BID) in subjects who are at least 2 years of age with mild-moderate AD.

Detailed Study Description

Approximately 600 subjects will be enrolled in the study, of which at least 150 subjects aged 2-6; at least 140 subjects aged 7-11; at least 120 subjects aged 12-17 and up to 90 subjects will be adults. Subjects must have mild-moderate AD involving at least 5% treatable %BSA assessed on baseline/Day 1. Treatable %BSA will be defined as the percent of a subject's total body surface area that is AD involved, excluding the scalp.

Eligible subjects will be randomized at the Baseline/Day 1 visit. Randomization will be stratified by eligibility for TCS or TCI treatment as per national approved labels. Cohort 1 will be for subjects who are eligible for TCS therapy, and Cohort 2 will be for subjects who are not eligible for TCS therapy but eligible for TCI therapy. The investigational products will be applied BID for 28 days to the Treatable body surface area (BSA) identified at Baseline/Day 1.

The primary efficacy endpoint is the percent change from baseline in the Eczema Area and Severity Index (EASI) total score at Day 29.

For the efficacy comparison of crisaborole versus vehicle, subjects from both Cohort 1 and Cohort 2 are included in the analysis, adjusted for cohort effect. For the efficacy comparison of crisaborole versus TCS, only subjects from Cohort 1 are included in the analysis. For the comparison of crisaborole versus TCI, only subjects from Cohort 2 are included in the analysis.

Safety and efficacy assessments will be conducted at the investigator site by a clinical assessor blinded to treatment assignment.

Scheduled study visits for all subjects will occur at Screening, Baseline/Day 1, Day 8, Day 15, Day 22, Day 29 (End of treatment/Early termination). A follow up telephone call will be made by site staff to the subjects/subject's legally acceptable guardian(s) on Day 36 and Day 60.

Clinical Study Identifier: NCT03539601

Contact Investigators or Research Sites near you

Start Over

Pfizer CT.gov Call Center

Dermatology Trial Associates
Bryant, AR United States
  Connect »

Pfizer CT.gov Call Center

Park Avenue Dermatology
Orange Park, FL United States
  Connect »

Pfizer CT.gov Call Center

Arlington Research Center Inc
Arlington, TX United States
  Connect »

Pfizer CT.gov Call Center

Virginia Clinical Research, Inc
Norfolk, VA United States
  Connect »

Pfizer CT.gov Call Center

California Dermatology & Clinical Research Institute
Encinitas, CA United States
  Connect »

Pfizer CT.gov Call Center

DS Research
Louisville, KY United States
  Connect »

Pfizer CT.gov Call Center

M3-Wake Research, Inc.
Raleigh, NC United States
  Connect »

Pfizer CT.gov Call Center

Forward Clinical Trials, Inc.
Tampa, FL United States
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.